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Results of cardiovascular outcome trials (CVOTs) suggest Asians may derive greater 
benefit than Whites with newer classes of antihyperglycemic medications.  
 
PURPOSE:  
To provide summary hazard ratio (HR) estimates for cardiovascular efficacy of 
sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 
receptor agonists (GLP-1RA) stratified by race (Asian vs. White).  
 
DATA SOURCES: 




Randomized placebo-controlled CVOTs of SGLT2is and GLP-1RAs that reported HR 
(95% CI) for (i) MACE, and (ii) cardiovascular (CV) death/ and hospitalization for 
heart failure (HHF).  
 
DATA EXTRACTION AND SYNTHESIS:  
The HR (95% CI) for selected outcomes in Asians and Whites was extracted from 
each trial, adhering to PRISMA guidelines. Random-effects meta-analyses were 




In 5 SGLT2i trials, the MACE outcome HR (95% CI) in 3,980 Asians vs. 29,007 
Whites was 0.81 (0.60, 1.01) vs. 0.86 (0.76, 0.97), respectively (pinteraction=0.64). In 2 
SGLT2i trials, the CV death/HHF outcome in 1,788 Asians vs. 5,962 Whites was 
0.60 (0.47, 0.74) vs. 0.82 (0.73, 0.92), respectively (pinteraction=0.01). In 6 GLP-1RA 
trials, the MACE outcome in 4,195 Asians vs. 37,530 Whites was 0.68 (0.53, 0.84) 
vs. 0.87 (0.81, 0.94), respectively (pinteraction=0.03).  
 
LIMITATIONS: 
Lack of individual patient-level data, relatively short duration of trial observation, and 
lack of granular categorization of race with the broadly-defined Asian subgroups.  
 
CONCLUSIONS: 
Compared with Whites, Asians may derive greater HHF/CV death benefit from 
SGLT2is and MACE benefit from GLP-1RA.  
 
PROSPERO registration number: CRD42020224993 
 
Key Words: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, meta-
analysis, race, ethnicity, Asian 
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INTRODUCTION 
Randomized trial results and their meta-analyses have demonstrated the 
cardiovascular (CV) benefits of novel antihyperglycemic medications for type 2 
diabetes such as sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-
like peptide receptor agonists (GLP-1RA) (1,2). Further, certain populations such as 
Asians, which form nearly 60% of the world’s population, including South Asians and 
East/Southeast Asians (collectively here categorized as ‘Asian’ due to the way most 
trials categorize race), experience a greater burden of type 2 diabetes compared 
with Whites, though they vary markedly in their risk for atherosclerotic cardiovascular 
disease (ASCVD) (3,4). Results from a recent meta-analysis pooling data for Asians 
with type 2 diabetes also indicated a significant reduction in major adverse 
cardiovascular events (MACE) with GLP-1RAs but not with SGLT2is compared with 
placebo in Asians. However, this study did not directly compare Asians vs. Whites, 
and did not consider all relevant SGLT2i trials (5).  
 
In the present paper, we meta-analyzed summary hazard ratio (HR) estimates from 
cardiovascular outcome trials (CVOTs) of SGLT2is and GLP-1RAs for effect 
modification of the efficacy of study drugs by race (Asian vs. White) with regard to 
selected CV outcomes. Of the antihyperglycemic drug classes, SGLT2is and GLP-
1RAs are the only ones to show consistent benefits on cardiovascular outcomes, 
and therefore we set out to examine only these two drug classes. 
 
METHODS 
Data Sources and Searches 
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A systematic review (PROSPERO registration number CRD42020224993) was 
performed in PubMed from January 01, 2015 to December 08, 2020 to identify 
published large, randomized placebo-controlled trials of SGLT2is and GLP-1RAs (6). 
Our search strategy is detailed in our Supplementary Fig. 1 PRISMA diagram.  
 
Study Selection 
Inclusion criteria included CVOTs of SGLT2is and GLP-1RAs providing effect size 
estimates (HR (95% confidence interval (CI)) for the outcomes of (i) MACE, and (ii) 
CV death/hospitalization for heart failure (HHF), in the subgroups of interest, e.g., 
Asians and Whites. Patients with and without type 2 diabetes were included.  
 
Data Extraction and Quality Assessment 
The HR (95% CI) for the outcomes of interest in Asians and Whites was extracted 
from each study by at least two researchers independently, adhering to Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
(7). Risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for 
randomized trials (RoB 2) (Supplementary Fig. S2) (8).  
 
Data Synthesis and Analysis 
We used the statistical software Stata/SE 16.0, using the Stata command ‘meta’ to 
perform a random effects model (DerSimonian and Laird method) meta-analysis (9). 
Our primary analyses compared CV outcomes reported by race of Asian and White, 




We identified 11 SGLT2i trials and 7 GLP-1RA trials (Supplementary Fig. S1 
PRISMA diagram).  
(10–17). 
 
Two SGLT2i trials (DECLARE-TIMI 58, SOLOIST-WHF) were excluded because the 
HR (95% CI) was not available for the subgroups of Asian and White patients 
(18,19). In SOLOIST-WHF, in the Asian subgroup, the HR could not be estimated 
due to 0 events in one of the treatment groups (19). Two further SGLT2i trials in 
patients with chronic kidney disease (CREDENCE, DAPA-CKD) were excluded 
because the reported outcomes available for Asian vs. White patients were neither 
MACE or CV death/HHF (13,14).  
 
Seven trials of SGLT2is were analyzed (Table 1): 5 diabetes trials (EMPA-REG 
OUTCOME, CANVAS Program (CANVAS and CANVAS-R), VERTIS CV, SCORED) 
reported MACE, and 2 heart failure trials (Dapa-HF, EMPEROR-Reduced) reported 
CV death/HHF (10–12,15–17).  
 
In 5 SGLT2i outcome trials including 3,980 Asian and 29,007 White patients with 
type 2 diabetes, the HR (95% CI) for the MACE outcome in Asian vs. White patients 
was 0.81 (0.60, 1.01) vs. 0.86 (0.76, 0.97) respectively (pinteraction=0.64) (Fig. 1).  
 
In 2 SGLT2i outcome trials including 1,788 Asian and 5,962 White patients with heart 
failure and reduced ejection fraction (HFrEF), the HR (95% CI) for CV death/HHF in 
Asian vs. White patients was 0.60 (0.47, 0.74) vs. 0.82 (0.73, 0.92) respectively 
(pinteraction=0.01) (Fig. 2).  
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One GLP-1RA trial (ELIXA) was excluded because the HR (95% CI) was not 
extractable for the subgroups of Asian and White patients (20).  
 
Six trials of GLP-1RAs were analyzed (Table 1): LEADER, SUSTAIN-6, EXSCEL, 
HARMONY OUTCOMES, REWIND, PIONEER 6 (21–26) reported MACE.  
 
In 6 GLP-1RA trials with 4,195 Asian and 37,530 White patients, the HR (95% CI) for 
the MACE outcome in Asian vs. White patients was 0.68 (0.53, 0.84) vs. 0.87 (0.81, 
0.94) respectively (pinteraction=0.03) (Fig. 3).  
 
DISCUSSION 
Results of clinical outcomes trials of SGLT2is and GLP-1RAs, comparing CV 
outcomes in Asians vs. Whites suggest differential treatment effects of SGLT2i (in 
those with HFrEF) and GLP-1RA by race, with greater benefits of both classes in 
Asians. Since the interaction between Asian race and outcomes seems consistent 
across different groups of studies, particular for the GLP-1RA class, it seems unlikely 
that random variation in baseline characteristics between trial arms explains the 
results.  
 
The recent meta-analysis by Singh and Singh of 3 SGLT2i trials found no significant 
reduction in MACE, HHF or CV death in Asians and postulated whether these results 
were due to low statistical power, underrepresentation of Asians, or a true ethnic 
difference (5). However, there appears benefit in terms of reduction in risk for CV 
death/HHF when the two HFrEF trials are meta-analyzed. This suggests that 
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SGLT2is lessen risk in Asians at least as well as in white Europeans and potentially 
better in patients with heart failure. Perhaps more significantly, we show GLP-1RA-
derived MACE benefits are significantly (pinteraction=0.03) better in Asians (mean 32% 
[16 to 47%] risk reduction) than in Whites (13% [6 to 19%]) with, remarkably, lower 
HRs in Asians vs. Whites in all of the 6 trials. In other words, GLP-1RAs have a 
~2.5-fold larger relative risk reduction for the MACE endpoint in Asians compared to 
Whites.  
 
These findings are all hypothesis generating and several limitations should be 
considered before concluding that such therapies, in particular GLP-1RA, lessen 
MACE risks more in Asians. Firstly, the Asian sub-population is often derived from 
several countries that collectively have a heterogeneous racial make-up, including 
East, South East and South Asians subgroups. While all Asian sub-groups are at 
elevated type 2 diabetes risk compared with Whites, their atherosclerotic 
cardiovascular disease risk can vary markedly, being higher in South Asians vs. 
Whites, but lower in other Asian subgroups (4). The findings are complex, however, 
as we noted lower CV mortality in South Asians compared to Whites in a recent 
observational study of people with type 2 diabetes (27). Furthermore, due to lack of 
breakdown of baseline characteristics by race in trials, it is not known to what extent 
Asian populations were (pre)treated with standard preventative therapies in each of 
the trials examined. It is possible that some Asian subgroups were less likely to be 
on comparative preventative therapy compared with Whites, leading to an apparent 
accentuated benefit seen with SGLT2i and/or GLP-1RA therapy in this treatment-




Alternatively, there may be other genuine biological explanations for these 
differences which merit future investigation. For example, as diabetes onset is earlier 
in Asian subgroups, and at lower body mass index (BMI), it may be that MACE or 
other cardiac risk driven by glycaemia affected pathways are more pronounced in 
Asian groups and that such pathways are better targeted by novel diabetes therapies 
(28,29). This is speculative, however, and more work is needed to determine if 
differences are genuine and if so, to determine potential mechanisms including 
effects on multiple risk pathways.  
 
There may have been differences in the proportion of Asian vs. White patients with 
type 2 diabetes and chronic kidney disease within the HF trials, although this 
information was not routinely available. A recent meta-analysis by Zannad et al of 
the two SGLT2i trials in patients with HFrEF showed no clear difference in outcomes 
by either diabetes status or eGFR levels above or below 60 ml/min/1.73m2 (30). 
Therefore, it seems unlikely that at least these characteristics explain any potential 
differences in HHF/CV death outcomes by ethnicity.  
 
Our meta-analysis has several limitations. Detailed analyses of specific sub-
populations of Asians are not possible from these trials due to limitations of relevant 
data collection. There was heterogeneity between the studies, in particular in the 
SGLT2i outcome trials, with I2 ranging from 0% to over 60%. That noted, there was 
far less heterogeneity within Asian and White groups in the analyses for which we 
report differences, namely for SGLT2i and heart failure, and in the GLP-1RA analysis 
(I2 up to maximum of 28.6%). Whilst not definitive, these findings lend some 
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confidence to the findings we report. The primary outcomes varied amongst the 5 
diabetes CVOTs vs. the 2 heart failure trials. Although trials reported data on Asians, 
as mentioned, data was lacking on more specific subgroups e.g., South Asians, East 
Asians or Southeast Asians. Definitions of race or ethnicity varied i.e., reported by 
patients in VERTIS CV, EMPEROR-Reduced, EXSCEL and HARMONY Outcomes, 
reported by investigators in SCORED and Dapa-HF, and not clearly specified in 
EMPA-REG OUTCOME, CANVAS Program, LEADER, SUSTAIN-6, REWIND or 
PIONEER 6. Our main goal, as pre-defined in PROSPERO, was to examine Asians 
vs. Whites, and therefore other races and ethnic groups were not analyzed. 
However, we feel that examining differences in other races and ethnic groups should 
form the basis of a separate report. Finally, individual patient-level data was not used 
for analyses, and therefore, we could not adjust for potential important differences 
such as duration of diabetes, baseline treatment, or baseline characteristics such as 
BMI or smoking histories, which vary between groups, which could have impacted 
the MACE and CV death/HHF outcomes.  
 
Going forwards, we suggest an individual participant meta-analysis would be 
informative when all trial data are made available, including looking at the risk of 
adverse effects by ethnic group. It might also be of interest to look at adherence to 
therapy and the proportion of people who completed the trial or dropped out by 
ethnic group. For example, it might be that Asians recruited into CVOTs are more 
“compliant” with therapy than whites are. Such possibilities could also be assessed 
through secondary analyses.  
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In conclusion, there is an apparent greater benefit of GLP-1RA therapy in Asians 
compared to whites across all classes of GLP-1RA so far tested. In addition, Asians 
have at least as good an effect of SGLT2is on MACE and potentially better for 
HHF/CV death outcomes than do whites. For future trials to be more informative, 
Asian race needs to be recorded with greater granularity, rather than grouping by 
geographic region. In particular, Asian race (a grouping that now covers nearly 60% 
the world’s population) should be broken down into more specific groups. We also 
suggest a need for more outcome-specific trials in Asian countries to further explore 
and validate the findings for GLP-1RAs. The findings of these analyses are relevant 
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Table 1 - SGLT2i and GLP-1RA trials 
Trial Year Population Primary Outcome Events/Patients, n/N Events/Patients, n/N Total Patients, N 
Asian White Asian White 
Treatment Placebo Treatment Placebo 




2015 Type 2 diabetes 
and high CV risk 
Composite of CV death / 




2017 Type 2 diabetes 
and high CV risk 
Composite of CV death / 
nonfatal MI / nonfatal stroke NR NR NR NR 1,284 7,944 
VERTIS CV 
(12) 
2020 Type 2 diabetes 
and ASCVD 
MACE (Composite of CV 
death / nonfatal MI / nonfatal 
stroke) 
36 / 336 19 / 161 573 / 4,820 278 / 2,413 497 7,233 
SCORED† 
(15) 
2020 Type 2 diabetes, 
chronic kidney 
disease and 
risks for CV 
disease 
Composite of total number of 
CV death / HFH / urgent visits 
for HF (original coprimary 
endpoints: first occurrence of 
CV death / nonfatal MI / 
nonfatal stroke and first 
occurrence of CV death / HFH) 
NR NR NR NR 682 8,749 
SGLT2i primary CV death / HFH outcome trials (1,788 Asian + 5,962 White) 
Dapa-HF 
(16) 
2019 HF with reduced 
ejection fraction, 
with and without 
type 2 diabetes 
Composite of worsening HF 
(hospitalization or urgent visit 
resulting in IV therapy for HF) / 
CV death 




2020 HF with reduced 
ejection fraction, 
with and without 
type 2 diabetes 
Composite of CV death / 
hospitalization for worsening 
HF 
62 / 337 99 / 335 264 / 1,325 289 / 1,304 672 2,629 
GLP-1RA primary MACE outcome trials (4,195 Asian + 37,530 White) 
LEADER 
(21) 
2016 Type 2 diabetes 
and high CV risk 
First occurrence of CV death / 
nonfatal MI / nonfatal stroke 
40 / 471 56 / 465 494 / 3,616 543 / 3,622 936 7,238 
SUSTAIN-6 
(22) 
2016 Type 2 diabetes 
and high CV risk 
First occurrence of CV death / 
nonfatal MI / nonfatal stroke 
8 / 121 17 / 152 93 / 1,384 118 / 1,352 273 2,736 
EXSCEL 
(23) 
2017 Type 2 diabetes 
with or without 
previous CV 
First occurrence of CV death / 






2018 Type 2 diabetes 
and CV disease 
First occurrence of CV death / 
MI / stroke 13 / 228 19 / 242 248 / 3,295 323 / 3,288 470 6,583 
REWIND 
(25) 
2019 Type 2 diabetes 
with previous CV 
disease or CV 
risk factors 
First occurrence of nonfatal MI 
/ nonfatal stroke / CV death 
21 / 216 30 / 218 462 / 3,754 505 / 3,744 434 7,498 
PIONEER 6 
(26) 
2019 Type 2 diabetes 
and high CV risk 
First occurrence of MACE (CV 
death / nonfatal MI / nonfatal 
stroke) 
9 / 324 19 / 306 46 / 1,148 55 / 1,152 630 2,300 
*CANVAS Program comprises of two trials, CANVAS and CANVAS-R. † Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1. 
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP-1RA, 
glucagon-like peptide-1 receptor agonist; HF, heart failure; HFH, heart failure hospitalization; IV, intravenous; MACE, major 





Figure 1 - SGLT2i cardiovascular outcome trials reporting MACE outcome by 
race 
 




Figure 2 - SGLT2i cardiovascular outcome trials reporting CV death/HHF 
outcome by race 
 
CV, cardiovascular; HHF, hospitalization for heart failure; SGLT2i, sodium-glucose 
co-transporter 2 inhibitor. 
 
 
Figure 3 - GLP-1RA cardiovascular outcome trials reporting MACE outcome by 
race 
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Heterogeneity: τ2 = 0.00, I2 = 26.68%, H2 = 1.36
Test of θi = θj: Q(5) = 2.49, p = 0.78
Test of θi = θj: Q(5) = 7.00, p = 0.22
Test of θi = θj: Q(11) = 15.00, p = 0.18
Test of group differences: Qb(1) = 4.87, p = 0.03
Study
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Random-effects DerSimonian-Laird model
